Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy: Randomized, Placebo-Controlled Study (FIRST)

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  2014-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/ATVBAHA.113.302926PMID 24743431
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis.

  2012cited by this paper
• Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants

  2012cited by this paper
• Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data.

  2012cited by this paper
• Carotid plaque burden as a measure of subclinical atherosclerosis: comparison with other tests for subclinical arterial disease in the High Risk Plaque BioImage study.

  2012cited by this paper
• The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

  2012cited by this paper
• Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).

  2012cited by this paper
• Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial

  2012cited by this paper
• Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy: The Treating to New Targets (TNT) Study

  2012cited by this paper
• Implications for Treatment

  2011cited by this paper
• Carotid-wall intima-media thickness and cardiovascular events.

  2011cited by this paper
• [Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study].

  2010cited by this paper
• Effects of combination lipid therapy in type 2 diabetes mellitus.

  2010cited by this paper
• Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials.

  2010cited by this paper
• Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report

  2009cited by this paper
• Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies.

  2009cited by this paper
• Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

  2009cited by this paper
• The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients

  2008cited by this paper
• Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.

  2008cited by this paper
• Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.

  2008cited by this paper
• Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome

  2008cited by this paper
• The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.

  2008cited by this paper
• Prediction of Clinical Cardiovascular Events With Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

  2005cited by this paper
• Effect of drugs on homocysteine concentrations.

  2005cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

  2000cited by this paper
• Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study

  1992cited by this paper
• Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment

  1992cited by this paper

• Emerging agents targeting triglycerides

  2025cites this paper
• Assessing the real-world safety of fenofibric acid for hyperlipidemia: results from WHO-VigiAccess and FAERS databases

  2025cites this paper
• Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in Patients with Dyslipidemia: A Randomized, Add-on Placebo-Controlled Clinical Trial.

  2023cites this paper
• Do patients benefit from omega-3 fatty acids?

  2023cites this paper
• A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes.

  2022cites this paper
• Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.

  2022cites this paper
• Serum triglycerides concentration in relation to total and cardiovascular mortality in an elderly Chinese population.

  2022cites this paper
• Perspective: Planning and Conducting Statistical Analyses for Human Nutrition Randomized Controlled Trials: Ensuring Data Quality and Integrity

  2021cites this paper
• Comparative efficacy of pharmacological agents on reducing the risk of major adverse cardiovascular events in the hypertriglyceridemia population: a network meta-analysis

  2021cites this paper
• Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites

  2020cites this paper
• Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk

  2020cites this paper
• Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid

  2020cites this paper
• Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro.

  2020cites this paper
• Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society.

  2020cites this paper
• Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society

  2020cites this paper
• IS MULTIPLE SCLEROSIS A RISK FACTOR FOR ATHEROSCLEROSIS?

  2019cites this paper
• Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis

  2019influential citation
• Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis

  2019cites this paper
• Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study

  2019cites this paper
• New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease

  2019cites this paper
• Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized study.

  2019cites this paper
• Management of Lipid Abnormalities in Patients with Diabetes

  2019cites this paper
• Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination

  2019cites this paper
• New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease

  2019cites this paper
• Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study

  2018cites this paper
• Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C

  2018cites this paper
• Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.

  2018cites this paper
• Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

  2018cites this paper
• Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid.

  2018cites this paper
• Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin.

  2018cites this paper
• Anti-Hypertensive Action of Fenofibrate via UCP2 Upregulation Mediated by PPAR Activation in Baroreflex Afferent Pathway

  2018cites this paper
• Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: Real-world results and factors associated with triglyceride reduction

  2018cites this paper
• Fibrates in the secondary prevention of cardiovascular disease (infarction and stroke). Results of a systematic review and meta-analysis of the Cochrane collaboration.

  2018cites this paper
• Definition of common carotid wall thickness affects risk classification in relation to degree of internal carotid artery stenosis: the Plaque At RISK (PARISK) study

  2017cites this paper
• Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?

  2017cites this paper
• Replacement of Refined Starches and Added Sugars with Egg Protein and Unsaturated Fats Increases Insulin Sensitivity and Lowers Triglycerides in Overweight or Obese Adults with Elevated Triglycerides.

  2017cites this paper
• Hypertriglyceridemia and atherosclerosis

  2017cites this paper
• Individual patient profiling using clinical and neuroradiological biomarkers in acute ischemic stroke: application of advanced multimodal neuroimaging

  2017cites this paper
• Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.

  2017cites this paper
• Dyslipidaemia: Small triumph for fenofibrate therapy in dyslipidaemia

  2017cites this paper
• Fibrates in the management of atherogenic dyslipidemia

  2017cites this paper
• In vivo ultrasound assessment of carotid artery walls and plaques : integrating morphological and mechanical characteristics

  2017cites this paper
• Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents

  2016cites this paper
• Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering

  2016cites this paper
• Fibrates for primary prevention of cardiovascular disease events.

  2016cites this paper
• Use of fibrates in the metabolic syndrome: A review.

  2016cites this paper
• Comparison of the safety of statin monotherapy and coadministration with fenofibrate in patients with mixed hyperlipidemia : a meta-analysis

  2016influential citation
• The future of n-3 polyunsaturated fatty acid therapy

  2016cites this paper
• Dyslipidemia Part 2

  2016cites this paper
• Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series

  2016cites this paper
• Fibrates for primary prevention of cardiovascular disease events.

  2016cites this paper
• Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus

  2016cites this paper
• Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease.

  2016cites this paper
• Peroxisome Proliferator-Activated Receptor α in Lipid Metabolism and Atherosclerosis.

  2015cites this paper
• Carotid intima-media thickness and carotid plaque represent different adaptive responses to traditional cardiovascular risk factors

  2015cites this paper
• Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia.

  2015cites this paper
• Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism.

  2015cites this paper
• Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising: A systematic review and meta-analysis of relevant preclinical studies and clinical trials.

  2015cites this paper
• Fibrates for secondary prevention of cardiovascular disease and stroke.

  2015cites this paper
• Measurements of carotid intima media thickness in non-invasive high-frequency ultrasound images: the effect of dynamic range setting

  2015cites this paper
• Fibrates and niacin: is there a place for them in clinical practice?

  2014cites this paper
• Simvastatin/fenofibrate combination in the treatment of dyslipidemia: current evidence

  2014cites this paper
• Beginning to understand high-density lipoproteins.

  2014cites this paper
• Atherosclerotic Plaque Imaging for Evaluation of HDL Targeting Therapy

  2014cites this paper
• Increased Hs-CRP/adiponectin ratio is associated with increase carotid intima-media thickness

  2014cites this paper